MindMed Bolsters Management Team
MindMed has appointed Peter Mack PhD as Vice President of Pharmaceutical Development.
- MindMed has appointed Peter Mack PhD as Vice President of Pharmaceutical Development.
MindMed (MNMD), a leading psychedelic-inspired medicine company has appointed Peter Mack PhD as Vice President of Pharmaceutical Development.
As MindMed progresses it’s Discover and Develop efforts for multiple commercial clinical programs including LSD and an ibogaine derivative, 18-MC, Peter will lead MindMed’s product development activities across its entire portfolio of investigational drugs. In addition, Peter will oversee partnerships with Contract Manufacturing Development Organizations and other discovery efforts to support the advancement of MindMed’s proprietary new chemical entities.
Peter joins MindMed from AstraZeneca, where he was the Director of Manufacturing for Inhalation Product Development. Peter previously worked at Pearl Therapeutics (acquired by AstraZeneca in 2013) where he helped pioneer the pharmaceutical development of inhaled combination therapies for highly prevalent respiratory diseases.
Peter holds a dual PhD in Medical Engineering / Medical Physics from Harvard Medical School and Massachusetts Institute of Technology (MIT), where he was a National Institute of Health (NIH) Biomechanics Training Grant Recipient. Peter also holds a Masters of Science in Mechanical Engineering from MIT. During his time in academia and the pharmaceutical industry, Peter contributed to numerous peer reviewed articles and patents.
“MindMed is constantly on the hunt to find the best people to help us shape the future of psychedelic medicine from discovery to delivery. We are excited to have Peter join us on our mission and help us craft a world class pharmaceutical development organization.”J.R. Rahn – Chief Executive Officer and Co-founder of MindMed
MindMed is a clinical-stage psychedelic medicine biotech company that discovers, develops and deploys psychedelic inspired medicines and therapies to address addiction and mental illness. The company is assembling a compelling drug development pipeline of innovative treatments based on psychedelic substances including Psilocybin, LSD, MDMA, DMT and an Ibogaine derivative, 18-MC. The MindMed executive team brings extensive biopharmaceutical experience to MindMed’s approach to developing the next generation of psychedelic inspired medicines and therapies.
MindMed trades on the NASDAQ under the symbol MNMD and on the Canadian NEO exchange under the symbol MMED. MindMed is also traded in Germany under the symbol MMQ.